These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 33452689)

  • 41. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
    Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
    Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19-Recovered Patients.
    Mahallawi WH; Fakher MH; Alsarani MA; Aljohani RH; Al-Mutabgani SA; Ibrahim NA
    Viral Immunol; 2022 Mar; 35(2):122-128. PubMed ID: 34747643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [
    Skawran S; Gennari AG; Dittli M; Treyer V; Muehlematter UJ; Maurer A; Burger IA; Mader C; Messerli O; Grünig H; Gebhard C; Huellner MW; Curioni-Fontecedro A; Berger C; Messerli M
    Eur Radiol; 2022 Jan; 32(1):508-516. PubMed ID: 34156552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein.
    Romero-Pinedo S; Quesada M; Horndler L; Álvarez-Fernández S; Olmo A; Abia D; Alarcón B; Delgado P
    Front Immunol; 2022; 13():809285. PubMed ID: 35296086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.
    Kounis NG; Koniari I; de Gregorio C; Velissaris D; Petalas K; Brinia A; Assimakopoulos SF; Gogos C; Kouni SN; Kounis GN; Calogiuri G; Hung MY
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
    Thompson MG; Burgess JL; Naleway AL; Tyner HL; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes A; Lutrick K; Kuntz JL; Dunnigan K; Odean MJ; Hegmann KT; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Groom HC; Zunie T; Thiese MS; Ivacic L; Wesley MG; Lamberte JM; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Harris KM; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
    MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):495-500. PubMed ID: 33793460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Lamb YN
    Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.
    Barbaud A; Garvey LH; Arcolaci A; Brockow K; Mori F; Mayorga C; Bonadonna P; Atanaskovic-Markovic M; Moral L; Zanoni G; Pagani M; Soria A; Jošt M; Caubet JC; Carmo A; Mona AA; Alvarez-Perea A; Bavbek S; Benedetta B; Bilo MB; Blanca-López N; Bogas HG; Buonomo A; Calogiuri G; Carli G; Cernadas J; Cortellini G; Celik G; Demir S; Doña I; Dursun AB; Eberlein B; Faria E; Fernandes B; Garcez T; Garcia-Nunez I; Gawlik R; Gelincik A; Gomes E; Gooi JHC; Grosber M; Gülen T; Hacard F; Hoarau C; Janson C; Johnston SL; Joerg L; Kepil Özdemir S; Klimek L; Košnik M; Kowalski ML; Kuyucu S; Kvedariene V; Laguna JJ; Lombardo C; Marinho S; Merk H; Meucci E; Morisset M; Munoz-Cano R; Murzilli F; Nakonechna A; Popescu FD; Porebski G; Radice A; Regateiro FS; Röckmann H; Romano A; Sargur R; Sastre J; Scherer Hofmeier K; Sedláčková L; Sobotkova M; Terreehorst I; Treudler R; Walusiak-Skorupa J; Wedi B; Wöhrl S; Zidarn M; Zuberbier T; Agache I; Torres MJ
    Allergy; 2022 Aug; 77(8):2292-2312. PubMed ID: 35112371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).
    Tuyls S; Van Der Brempt X; Faber M; Gadisseur R; Dezfoulian B; Schrijvers R; Froidure A;
    Acta Clin Belg; 2022 Jun; 77(3):552-557. PubMed ID: 33792500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COVID-19 mRNA vaccine allergy.
    Risma KA
    Curr Opin Pediatr; 2021 Dec; 33(6):610-617. PubMed ID: 34670264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.
    Sampath V; Rabinowitz G; Shah M; Jain S; Diamant Z; Jesenak M; Rabin R; Vieths S; Agache I; Akdis M; Barber D; Breiteneder H; Chinthrajah S; Chivato T; Collins W; Eiwegger T; Fast K; Fokkens W; O'Hehir RE; Ollert M; O'Mahony L; Palomares O; Pfaar O; Riggioni C; Shamji MH; Sokolowska M; Jose Torres M; Traidl-Hoffmann C; van Zelm M; Wang Y; Zhang L; Akdis CA; Nadeau KC
    Allergy; 2021 Jun; 76(6):1640-1660. PubMed ID: 33811364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.